OraSure Technologies Newswire

OraSure Technologies Newswire

Comprehensive Real-Time News Feed for OraSure Technologies.

Results 1 - 20 of 236 in OraSure Technologies

  1. OraSure Technologies (OSUR) Upgraded by BidaskClub to "Strong-Buy"Read the original story w/Photo

    16 hrs ago | AmericanBankingNews.com

    A number of other research firms also recently issued reports on OSUR. Zacks Investment Research downgraded shares of OraSure Technologies from a "buy" rating to a "hold" rating in a research report on Saturday, November 4th.

    Comment?

  2. OraSure Technologies Earnings Conference Call InvitationRead the original story w/Photo

    Wednesday Jan 17 | GlobeNewswire

    OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2017 fourth quarter financial results, 2018 first quarter financial guidance and certain business developments for 5:00 pm ET on Wednesday, February 7, 2018. The conference call will also be webcast live and may be accessed on the Investor Relations page of OraSure's website, www.orasure.com .

    Comment?

  3. $47.97 Million in Sales Expected for OraSure Technologies, Inc. (OSUR) This QuarterRead the original story w/Photo

    Sunday Jan 14 | AmericanBankingNews.com

    Analysts expect OraSure Technologies, Inc. to announce $47.97 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for OraSure Technologies' earnings.

    Comment?

  4. OraSure Technologies (OSUR) Upgraded at Zacks Investment ResearchRead the original story w/Photo

    Friday Jan 12 | The Breeze

    According to Zacks, "OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

    Comment?

  5. OraSure Technologies (OSUR) Rating Increased to Hold at Zacks Investment ResearchRead the original story w/Photo

    Tuesday Jan 9 | AmericanBankingNews.com

    According to Zacks, "OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

    Comment?

  6. Why OraSure Technologies, Inc. Rallied 10.8% in DecemberRead the original story w/Photo

    Friday Jan 5 | Fox News

    ... thinks it is a good idea to look elsewhere for investment opportunities. 10 stocks we like better than OraSure Technologies When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run ...

    Comment?

  7. University City Science Center Announces CEO TransitionRead the original story w/Photo

    Thursday Jan 4 | PRWeb

    The University City Science Center announced today that Stephen S. Tang, Ph.D., MBA, will step down as President & CEO to join OraSure Technologies Inc. as President & CEO. I am excited about the Science Center's future and momentum and believe the foundation has been laid for continued growth and success.

    Comment?

  8. Global Genomics Personalized Health Market to Become Worth US$25,112.5 Mn During Forecast 2017-2024Read the original story w/Photo

    Wednesday Jan 3 | SBWire

    ... Limited, Interleukin Genetics Inc., Eastern Biotech and Life Sciences, DNA Genotek Inc. (Subsidiary of OraSure Technologies, Inc.),uBiome, Inc., and XCode Life Sciences Private Limited. About ResearchMoz ResearchMoz is the world's fastest growing ...

    Comment?

  9. Recro Pharma Announces Key Executive Promotions to the Financial TeamRead the original story

    Wednesday Jan 3 | Customer Interaction Solutions

    ... company, and BioRexis, a venture-funded, life sciences company. Mr. Celano serves on the board of Orasure Technologies (Nasdaq:OSUR). Prior to entering the biopharmaceutical industry, Mr. Celano was a Partner at Arthur Andersen/KPMG, where he worked ...

    Comment?

  10. Cadence Capital Management Has Trimmed Its Orasure Technologies...Read the original story

    Wednesday Jan 3 | Hill Country Times

    Cadence Capital Management Llc decreased Orasure Technologies Inc stake by 41.39% reported in 2017Q3 SEC filing. Cadence Capital Management Llc sold 51,781 shares as Orasure Technologies Inc 's stock rose 29.30%.

    Comment?

  11. Zacks Investment Research Upgrades OraSure Technologies (OSUR) to HoldRead the original story w/Photo

    Tuesday Jan 2 | IntersportsWire

    According to Zacks, "OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

    Comment?

  12. Somewhat Positive Press Coverage Somewhat Unlikely to Affect OraSure Technologies (OSUR) Stock PriceRead the original story w/Photo

    Monday Jan 1 | IntersportsWire

    Media coverage about OraSure Technologies has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources.

    Comment?

  13. OraSure Technologies (OSUR) Upgraded at Zacks Investment ResearchRead the original story w/Photo

    Saturday Dec 30 | AmericanBankingNews.com

    According to Zacks, "OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

    Comment?

  14. OraSure Technologies, Inc. (OSUR) Expected to Post Quarterly Sales of $45.27 MillionRead the original story w/Photo

    Friday Dec 29 | The Breeze

    Equities analysts forecast that OraSure Technologies, Inc. will report sales of $45.27 million for the current fiscal quarter, according to Zacks Investment Research . Two analysts have made estimates for OraSure Technologies' earnings.

    Comment?

  15. Head-To-Head Review: SterisRead the original story w/Photo

    Wednesday Dec 27 | The Breeze

    Steris and OraSure Technologies are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends. Steris has higher revenue and earnings than OraSure Technologies.

    Comment?

  16. $0.09 EPS Expected for OraSure Technologies, Inc. (OSUR) This QuarterRead the original story w/Photo

    Wednesday Dec 27 | AmericanBankingNews.com

    Wall Street brokerages expect OraSure Technologies, Inc. to report earnings per share of $0.09 for the current fiscal quarter, according to Zacks Investment Research . Two analysts have issued estimates for OraSure Technologies' earnings.

    Comment?

  17. Steris (STE) vs. OraSure Technologies (OSUR) Financial ContrastRead the original story w/Photo

    Saturday Dec 23 | AmericanBankingNews.com

    Steris and OraSure Technologies are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability. Steris has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

    Comment?

  18. Monarch Capital Management Has Lifted By $321,975 Its Gilead Sciences ...Read the original story

    Friday Dec 22 | Hill Country Times

    Monarch Capital Management Has Lifted By $321,975 Its Gilead Sciences Holding; 4 Analysts Bullish OraSure Technologies, Inc. Among 6 analysts covering OraSure Technologies , 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive.

    Comment?

  19. OraSure Technologies (OSUR) Lifted to Buy at BidaskClubRead the original story w/Photo

    Thursday Dec 21 | AmericanBankingNews.com

    A number of other research firms have also commented on OSUR. Zacks Investment Research lowered OraSure Technologies from a "buy" rating to a "hold" rating in a research report on Wednesday, October 4th.

    Comment?

  20. Sientra (SIEN) vs. OraSure Technologies (OSUR) Head-To-Head AnalysisRead the original story w/Photo

    Dec 19, 2017 | Daily Political

    Sientra and OraSure Technologies are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk. Sientra has a beta of -1.47, indicating that its share price is 247% less volatile than the S&P 500.

    Comment?